WO1998036763A9 - Treatment of infertility with leptin receptor ligands - Google Patents
Treatment of infertility with leptin receptor ligandsInfo
- Publication number
- WO1998036763A9 WO1998036763A9 PCT/US1998/002909 US9802909W WO9836763A9 WO 1998036763 A9 WO1998036763 A9 WO 1998036763A9 US 9802909 W US9802909 W US 9802909W WO 9836763 A9 WO9836763 A9 WO 9836763A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leptin receptor
- leptin
- puberty
- treating
- treatment
- Prior art date
Links
- 108010019813 leptin receptors Proteins 0.000 title claims abstract description 57
- 102000005861 leptin receptors Human genes 0.000 title claims abstract description 25
- 208000000509 Infertility Diseases 0.000 title claims abstract description 20
- 230000036512 infertility Effects 0.000 title claims abstract description 20
- 231100000535 infertility Toxicity 0.000 title claims abstract description 16
- 230000027455 binding Effects 0.000 title claims description 29
- 239000003446 ligand Substances 0.000 title claims description 27
- 239000000018 receptor agonist Substances 0.000 claims abstract description 26
- 235000016709 nutrition Nutrition 0.000 claims abstract description 13
- 230000035764 nutrition Effects 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N Leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 33
- 102000016267 Leptin Human genes 0.000 claims description 33
- 108010092277 Leptin Proteins 0.000 claims description 33
- 229940039781 leptin Drugs 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 28
- 108090001123 antibodies Proteins 0.000 claims description 11
- 102000004965 antibodies Human genes 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000002464 receptor antagonist Substances 0.000 claims description 11
- 208000006155 Precocious Puberty Diseases 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 8
- 230000035558 fertility Effects 0.000 claims description 8
- 206010012205 Delayed puberty Diseases 0.000 claims description 5
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 102100017662 LEPR Human genes 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 15
- 239000000969 carrier Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 12
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 8
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 8
- -1 His Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 6
- 229920001850 Nucleic acid sequence Polymers 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003016 Hypothalamus Anatomy 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 108010045030 monoclonal antibodies Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 4
- 210000000577 Adipose Tissue Anatomy 0.000 description 4
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 210000004027 cells Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000002068 genetic Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- 102000005614 monoclonal antibodies Human genes 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 231100000803 sterility Toxicity 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 3
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical group CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 3
- 125000000773 L-serino group Chemical group [H]OC(=O)[C@@]([H])(N([H])*)C([H])([H])O[H] 0.000 description 3
- 108020004999 Messenger RNA Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004185 hypothalamic-pituitary-gonadal axis Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920002106 messenger RNA Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 125000003290 L-leucino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 125000000205 L-threonino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])[C@](C([H])([H])[H])([H])O[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- DVCSNHXRZUVYAM-BQBZGAKWSA-N Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 2
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 2
- XGDCYUQSFDQISZ-BQBZGAKWSA-N Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O XGDCYUQSFDQISZ-BQBZGAKWSA-N 0.000 description 2
- YQAIUOWPSUOINN-IUCAKERBSA-N Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN YQAIUOWPSUOINN-IUCAKERBSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229940113082 Thymine Drugs 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010017391 lysylvaline Proteins 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BLEMLGBVQSNDOD-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CN=C2[C]1C(Cl)=C(Br)C=C2 BLEMLGBVQSNDOD-AEOCFKNESA-N 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- HZYFHQOWCFUSOV-IMJSIDKUSA-N Asn-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O HZYFHQOWCFUSOV-IMJSIDKUSA-N 0.000 description 1
- KWBQPGIYEZKDEG-FSPLSTOPSA-N Asn-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O KWBQPGIYEZKDEG-FSPLSTOPSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- LVNMAAGSAUGNIC-UHFFFAOYSA-N Cysteinyl-Histidine Chemical compound SCC(N)C(=O)NC(C(O)=O)CC1=CN=CN1 LVNMAAGSAUGNIC-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-XVFCMESISA-N Cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 description 1
- 210000002149 Gonads Anatomy 0.000 description 1
- 229920001681 Heteroduplex Polymers 0.000 description 1
- LNCFUHAPNTYMJB-IUCAKERBSA-N His-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNCFUHAPNTYMJB-IUCAKERBSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 1
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 1
- UASDAHIAHBRZQV-YUMQZZPRSA-N Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N UASDAHIAHBRZQV-YUMQZZPRSA-N 0.000 description 1
- QTZXSYBVOSXBEJ-WDSKDSINSA-N Met-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O QTZXSYBVOSXBEJ-WDSKDSINSA-N 0.000 description 1
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000002041 N(2)-L-arginino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- 102100015978 NPY Human genes 0.000 description 1
- 108020001430 NPY Proteins 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N Neuropeptide Y(NPY) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- 102100008873 POMC Human genes 0.000 description 1
- 108060006375 POMC Proteins 0.000 description 1
- ROHDXJUFQVRDAV-UWVGGRQHSA-N Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ROHDXJUFQVRDAV-UWVGGRQHSA-N 0.000 description 1
- 210000003635 Pituitary Gland Anatomy 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 1
- NFDYGNFETJVMSE-BQBZGAKWSA-N Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CO NFDYGNFETJVMSE-BQBZGAKWSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- RZEQTVHJZCIUBT-UHFFFAOYSA-N Serinyl-Arginine Chemical compound OCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RZEQTVHJZCIUBT-UHFFFAOYSA-N 0.000 description 1
- 229920000978 Start codon Polymers 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- YKRQRPFODDJQTC-UHFFFAOYSA-N Threoninyl-Lysine Chemical compound CC(O)C(N)C(=O)NC(C(O)=O)CCCCN YKRQRPFODDJQTC-UHFFFAOYSA-N 0.000 description 1
- 229940100615 Topical Ointment Drugs 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- OHGNSVACHBZKSS-KWQFWETISA-N Trp-Ala Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)N[C@@H](C)C([O-])=O)=CNC2=C1 OHGNSVACHBZKSS-KWQFWETISA-N 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 1
- GVRKWABULJAONN-UHFFFAOYSA-N Valyl-Threonine Chemical compound CC(C)C(N)C(=O)NC(C(C)O)C(O)=O GVRKWABULJAONN-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000001919 adrenal Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N dCyd Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 235000020828 fasting Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- STKYPAFSDFAEPH-LURJTMIESA-N gly-val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 230000002710 gonadal Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000030623 human LEP protein Human genes 0.000 description 1
- 108091003235 human LEP protein Proteins 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000002294 pubertal Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 230000035938 sexual maturation Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N β-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- This invention relates generally to a method for treating the infertility associated with improper nutrition in a mammal in need of such treatment by administration of a therapeutically effective amount of a leptin receptor agonist.
- Improper nutrition can lead to fertility problems: delay in onset of puberty, abnormal menstrual cycles, and sterility in females. In obese males, fertility is also greatly reduced. It has been reported that leptin levels in obese patients are higher than in lean patients and that starvation reduces leptin levels in blood.
- F. Chehab (Chehab, F.F. et al. (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics, 12:318-320) showed that the sterility in ob/ob mice can be corrected by treatment with human leptin.
- Leptin administration to starved mice tends to reverse the effects of starvation on testosterone and LH levels (Ahima, R.S. et al. (1996) Leptin is a major mediator of the neuroendocrine response to fasting. Submitted). Additional evidence for a role of leptin in the hypothalamic- pituitary-gonadal axis (HPG) derives from the distribution of the long form of OB-R that is abundant in the gonads as well as the hypothalamus (Lee, G.H. et al. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature 379:632-635).
- HPG hypothalamic- pituitary-gonadal axis
- NPY neuropeptide Y
- a major object of the present invention is to provide a method of treating the infertility associated with improper nutrition.
- Leptin used as an adjunct in weight loss programs would not only aid the weight loss itself but could prevent fertility problems that were induced by a rapid drop in leptin levels.
- leptin receptor ligands represent an opportunity for therapy in conditions associated with either abnormally low or high adiposity, or relative leptin deficiency.
- infertility in subjects with low adiposity may be restored by exogenous leptin administration.
- Delayed puberty may be treated with a leptin regimen.
- This invention discloses the utility of leptin, leptin mimetics, or novel leptin analogs to treat fertility disorders and delayed puberty in either obese or lean subjects.
- leptin antagonists or neutralizing antileptin antibodies may be used to treat precocious puberty.
- This invention arose from a desire of the inventors to provide a safe, effective treatment for infertility, in particular a treatment which would prevent or inhibit the infertility associated with improper nutrition in a mammal in need of such treatment.
- Base pair (bp) -- refers to DNA or RNA.
- the abbreviations A,C,G, and T correspond to the 5'-monophosphate forms of the nucleotides (deoxy)adenine, (deoxy)cytidine, (deoxy)guanine, and (deoxy)thymine, respectively, when they occur in DNA molecules.
- the abbreviations U,C,G, and T correspond to the 5'-monophosphate forms of the nucleosides uracil, cytidine, guanine, and thymine, respectively when they occur in RNA molecules.
- base pair may refer to a partnership of A with T or C with G.
- base pair may refer to a partnership of T with U or C with G.
- Chelating Peptide An amino acid sequence capable of complexing with a multivalent metal ion.
- DNA Deoxyribonucleic acid.
- HPAAA Hypothalamic-Pituitary-Adrenal-Adipose Axis
- CRH released by the hypothalamus stimulates pituitary secretion of ACTH, that in turn stimulates adrenal secretion of glucocorticoids, which in turn modulates adipose tissue leptin release, that finally acts back on the hypothalamus.
- Immunoreactive Protein(s) a term used to collectively describe antibodies, fragments of antibodies capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived, and single chain polypeptide binding molecules as described in PCT Application No. PCT/US 87/02208, International Publication No. WO 88/01649.
- mRNA messenger RNA.
- MWCO an abbreviation for molecular weight cut-off.
- Modulating - stimulation, potentiation, or inhibition of the activity of a receptor or system Modulating - stimulation, potentiation, or inhibition of the activity of a receptor or system.
- Plasmid an extrachromosomal self-replicating genetic element.
- PMSF an abbreviation for phenylmethylsulfonyl fluoride.
- Reading frame the nucleotide sequence from which translation occurs "read” in triplets by the translational apparatus of tRNA, ribosomes and associated factors, each triplet corresponding to a particular amino acid. Because each triplet is distinct and of the same length, the coding sequence must be a multiple of three. A base pair insertion or deletion (termed a frameshift mutation) may result in two different proteins being coded for by the same DNA segment.
- the triplet codons corresponding to the desired polypeptide must be aligned in multiples of three from the initiation codon, i.e. the correct "reading frame" must be maintained.
- the reading frame of the DNA sequence encoding the structural protein must be maintained in the DNA sequence encoding the chelating peptide.
- Receptor agonist any compound that binds to a receptor and triggers the action of the receptor (usually an intracellular signalling event or, in the case of receptors that form transmembrane channel, the opening or closing of the channel).
- Receptor antagonist any compound that binds to a receptor and blocks the action of the receptor (usually by out-competing the endogenous agonist for binding sites on the receptor).
- Receptor ligand any compound that binds to a receptor.
- Recombinant DNA Cloning Vector any autonomously replicating agent including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been added.
- Recombinant DNA Expression Vector any recombinant DNA cloning vector in which a promoter has been incorporated.
- Replicon - A DNA sequence that controls and allows for autonomous replication of a plasmid or other vector.
- RNA - ribonucleic acid A DNA sequence that controls and allows for autonomous replication of a plasmid or other vector.
- Transcription the process whereby information contained in a nucleotide sequence of DNA is transferred to a complementary RNA sequence.
- Tris - an abbreviation for tris-(hydroxymethyl)aminomethane.
- Treating - describes the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a leptin receptor ligand of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- Treating obesity for example, includes the inhibition of food intake, the inhibition of weight gain, and inducing weight loss in patients in need thereof.
- Vector - a replicon used for the transformation of cells in gene manipulation bearing polynucleotide sequences corresponding to appropriate protein molecules which, when combined with appropriate control sequences, confer specific properties on the host cell to be transformed.
- Plasmids, viruses, and bacteriophage are suitable vectors, since they are replicons in their own right.
- Artificial vectors are constructed by cutting and joining DNA molecules from different sources using restriction enzymes and ligases. vectors include Recombinant DNA cloning vectors and Recombinant DNA expression vectors.
- X-gal - an abbreviation for 5-bromo-4-chloro-3-idolyl beta-D- galactoside.
- Leptin receptor agonists may be used to treat fertility disorders and delayed puberty.
- leptin antagonists alone or combined with specific antibodies to leptin, may be used to treat precocious puberty.
- proteins include a leader sequence such as Met-Asp or Met-Arg, or altered primary sequence to achieve higher physical stability.
- leptin receptor ligands in particular leptin receptor agonists or leptin receptor antagonists
- receptor ligands in particular leptin receptor agonists or leptin receptor antagonists
- receptor antagonists used herein are understood to refer to pharmacologically active compounds, and to salts thereof.
- Preferred leptin receptor agonists for use in the present invention include endogenous leptin (i.e., endogenous OB protein - the protein produced from the obesity gene following transcription and translation and deletion of introns, translation to a protein and processing to the mature protein with secretory signal peptide removed, e.g., from the N-terminal valine-proline to the C- terminal cysteine of the mature protein).
- endogenous leptin i.e., endogenous OB protein - the protein produced from the obesity gene following transcription and translation and deletion of introns, translation to a protein and processing to the mature protein with secretory signal peptide removed, e.g., from the N-terminal valine-proline to the C- terminal cysteine of the mature protein.
- the mouse OB protein and human OB protein are published in Zhang et al., Nature 372:425-432 (1994).
- the rat OB protein is published in Murakami et al., Biochem
- the porcine and bovine OB genes and proteins are disclosed in EP 0 743 321 , the contents of which are incorporated by reference.
- Various primate OB genes and proteins are disclosed in U.S. Application Serial No.08/710,483, the contents of which are incorporated by reference.
- Also preferred for use in the present invention are leptin analogs, preferably leptin analogs having one or more amino acid substitution, more preferably less than five and most preferably less than three substitutions.
- Particularly preferred leptin analogs for use in the present invention include proteins disclosed by Basinski et al., in WO 96/23515 and WO 96/23517 (the contents of which are incorporated by reference), of the Formula (I):
- Xaa at position 28 is Gin or absent; said protein having at least one of the following substitutions:
- Gin at position 4 is replaced with Glu
- Thr at position 27 is replaced with Ala
- Xaa at position 28 is replaced with Glu
- Gin at position 34 is replaced with Glu
- Met at position 54 is replaced with methionine sulfoxide, Leu, lie, Val, Ala, or Gly;
- Gin at position 56 is replaced with Glu
- Gin at position 62 is replaced with Glu
- Gin at position 63 is replaced with Glu
- Met at position 68 is replaced with methionine sulfoxide, Leu, lie, Val, Ala, or Gly;
- Asn at position 72 is replaced with Gin, Glu, or Asp;
- Gin at position 75 is replaced with Glu
- His at position 97 is replaced with Gin, Asn, Ala, Gly, Ser, or Pro;
- Trp at position 100 is replaced with Ala, Glu, Asp, Asn, Met, lie, Phe, Tyr, Ser, Thr, Gly, Gin, Val, or Leu;
- Ala at position 101 is replaced with Ser, Asn, Gly, His, Pro, Thr, or Val;
- Ser at position 102 is replaced with Arg; Gly at position 103 is replaced with Ala;
- Glu at position 105 is replaced with Gin
- Thr at position 106 is replaced with Lys or Ser;
- Leu at position 107 is replaced with Pro; Asp at position 108 is replaced with Glu;
- Gly at position 111 is replaced with Asp
- Gin at position 130 is replaced with Glu
- Gin at position 134 is replaced with Glu; Met at position 136 is replaced with methionine sulfoxide, Leu, lie,
- Trp at position 138 is replaced with Ala, Glu, Asp, Asn, Met, lie, Phe, Tyr, Ser, Thr, Gly, Gin, Val, or Leu; or
- the leptin receptor ligands of the present invention are optionally substituted with a functional group. Any art-recognized functional group which does not eliminate or significantly reduce the compound's ability to bind to leptin receptors are contemplated, including, but not limited to, ester, amide, acid, amine, alcohol, ether, thioether, etc. Solvates, e.g., hydrates of the compounds useful in the methods of the present invention, are also included within the scope of the present invention. Methods of solvation to produce such solvates are generally known in the art.
- compositions of the leptin receptor agonists and antagonists suitable for administration by a variety of routes are known in the art and need not be described herein in detail.
- pharmaceutically acceptable salts of the leptin receptor ligands and derivatives thereof according to the invention include base salts, e.g., derived from an appropriate base.
- Pharmaceutically acceptable salts of an acid group or an amino group include, but are not limited to, salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isothionic, and lactobionic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-tolylsuifonic acids, and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids.
- Pharmaceutically- acceptable salts of a compound with a hydroxy group include, but are not limited to, the anion of the compound in combination with a suitable cation such as Na + .
- a further embodiment of the present invention comprises a method for treating the infertility associated with improper nutrition by administration of antibodies to endogenous leptin receptor agonists to a mammal in need of such treatment.
- Such antibodies may be monoclonal or polyclonal antibodies to leptin receptor agonists, or to antigenic parts thereof.
- Both polyclonal and monoclonal antibodies to leptin receptor agonists are obtainable by immunization of an animal with purified leptin receptor agonists, purified recombinant leptin receptor agonists, fragments of these proteins, or purified fusion proteins of leptin receptor agonists, with another protein.
- partially purified proteins or fragments may serve as immunogens.
- the methods of obtaining both types of antibodies are well known in the art with excellent protocols for antibody production being found in Harlow et al. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 726 pp.
- Polyclonal sera are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of purified leptin receptor agonists, or parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques.
- Monoclonal antibodies are particularly useful because they can be produced in large quantities and with a high degree of homogeneity.
- Hybridoma cell lines which produce monoclonal antibodies are prepared by fusing an immortal cell line with lymphocytes sensitized against the immunogenic preparation and is done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard, I.Y. and Hoffman, T., "Basic Facts About Hybridomas", in Compendium of Immunology, Vol. II, L.
- a still further part of this invention is a pharmaceutical composition of matter for treating the infertility associated with improper nutrition that comprises at least one of the leptin receptor agonists or antagonists described above, mixtures thereof, and/or pharmaceutical salts thereof, and a pharmaceutically-acceptable carrier therefor.
- Such compositions are prepared in accordance with accepted pharmaceutical procedures, for example, as described in Remington's Pharmaceutical Sciences, seventeenth edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
- a leptin receptor agonist or antagonist, or its salt can be conveniently administered in the form of a pharmaceutical composition containing one or more leptin receptor agonists or . antagonists, or salts thereof, and a pharmaceutically acceptable carrier therefor.
- Suitable carriers are well known in the art and vary with the desired form and mode of administration of the pharmaceutical composition. For example, they may include diluents or excipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, lubricants, and the like.
- the carrier may be a solid, liquid, or vaporizable carrier, or combinations thereof.
- the composition is a therapeutic composition and the carrier is a pharmaceutically acceptable carrier.
- the leptin receptor ligands for use in the present invention, or salts thereof, may be formulated together with the carrier into any desired unit dosage form.
- Typical unit dosage forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories; injectable solutions and suspensions are particularly preferred.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients in the formulation and not injurious to the patient.
- the carrier must be biologically acceptable and inert, i.e., it must permit the cell to conduct its metabolic reactions so that the leptin receptor ligands suitable for use in the method of the present invention may effect its inhibitory activity.
- Formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and transdermal) administration, with topical ointment formulations, and formulations appropriate for oral administration, being preferred.
- solutions and suspensions are sterilized and are preferably isotonic to blood.
- carriers which are commonly used in this field can also be used, for example, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitate esters.
- isotonicity adjusters such as sodium chloride, glucose or glycerin can be added to make the preparations isotonic.
- the aqueous sterile injection solutions may further contain anti-oxidants, buffers, bacteriostats, and like additions acceptable for parenteral formulations.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which may encompass one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. Various unit dose and multidose containers, e.g., sealed ampules and vials, may be used, as is well known in the art. In addition to the ingredients particularly mentioned above, the formulations of this invention may also include other agents conventional in the art for this type of pharmaceutical formulation.
- the leptin receptor ligands suitable for use in the present invention may be present in the composition in an broad proportion to the carrier.
- the leptin receptor ligands may be present in the amount of 0.01 to 99.9 wt%, and more preferably in about 0.1 to 99 wt%. Still more preferably, the leptin receptor ligand may be present in an amount of about 1 to 70 wt% of the composition.
- the dosage of the leptin receptor agonists or antagonists, pharmaceutically acceptable salts thereof, or mixtures thereof administered to a patient according to the present invention will vary depending on several factors, including, but not limited to, the age, weight, and species of the patient, the general health of the patient, the severity of the symptoms, whether the composition is being administered alone or in combination with other therapeutic agents, the incidence of side effects and the like.
- a dose suitable for application in treating the infertility associated with improper nutrition is about 0.001 to 100 mg/kg body weight/dose, preferably about 0.01 to 60 mg/kg body weight/dose, and still more preferably about 0.1 to 40 mg/kg body weight/dose per day.
- the desired dose may be administered as 1 to 6 or more subdoses administered at appropriate intervals throughout the day.
- the leptin receptor ligands may be administered repeatedly over a period of months or years, or it may be slowly and constantly infused to the patient. Higher and lower doses may also be administered.
- the daily dose may be adjusted taking into account, for example, the above-identified variety of parameters.
- the present compositions may be administered in an amount of about 0.001 to 100 mg/kg body weight/day. However, other amounts may also be administered.
- leptin receptor ligands suitable for use in the present invention may be administered, for instance, by intravenous injection of an approximate 0.1 to 1% solution of the active ingredient, optionally in saline, or orally administered as a bolus.
- the active ingredient may be administered for therapy by any suitable routes, including topical, oral, rectal, nasal, vaginal and parenteral (including intraperitoneal, subcutaneous, intramuscular, intravenous, intradermal, and transdermal) routes. It will be appreciated that the preferred route will vary with the condition and age of the patient, the nature of the disorder and the chosen active ingredient including other therapeutic agents. Preferred is the oral route. Also preferred is the topical route. However, other routes may also be utilized depending on the conditions of the patient and how long-lasting the treatment is.
- the active ingredient While it is possible for the active ingredient to be administered alone, it is preferably present as a pharmaceutical formulation.
- the formulations of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents.
- the above method may be practiced by administration of leptin receptor ligands by themselves or in a combination with other active ingredients, including therapeutic agents in a pharmaceutical composition.
- Other therapeutic agents suitable for use herein are any compatible drugs that are effective by the same or other mechanisms for the intended purpose, or drugs that are complementary to those of the present agents. These include agents that are effective for the treatment of infertility and/or associated conditions in humans.
- the compounds utilized in combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times than the present compounds, e.g., sequentially, such that a combined effect is achieved.
- the amounts and regime of administration will be adjusted by the practitioner, by preferably initially lowering their standard doses and then titrating the results obtained.
- the therapeutic method of the invention may be used in conjunction with other therapies as determined by the practitioner. While the invention has been described and illustrated herein by references to various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material, combinations of material, and procedures selected for that purpose. Numerous variations of such details can be implied and will be appreciated by those skilled in the art.
Abstract
This invention relates generally to a method for treating the infertility associated with improper nutrition in a mammal in need of such treatment by administration of a therapeutically effective amount of a leptin receptor agonist.
Description
TREATMENT OF INFERTILITY WITH LEPTIN RECEPTOR LIGANDS
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to a method for treating the infertility associated with improper nutrition in a mammal in need of such treatment by administration of a therapeutically effective amount of a leptin receptor agonist.
2. Description of the Related Art
Improper nutrition (both undemutrition and obesity) can lead to fertility problems: delay in onset of puberty, abnormal menstrual cycles, and sterility in females. In obese males, fertility is also greatly reduced. It has been reported that leptin levels in obese patients are higher than in lean patients and that starvation reduces leptin levels in blood. F. Chehab (Chehab, F.F. et al. (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics, 12:318-320) showed that the sterility in ob/ob mice can be corrected by treatment with human leptin.
The consistent finding that leptin levels relate to gender and puberty, even with correction for percentage of body fat, suggests a rule that is not limited to the lipostat (Hassink, S.G., et al. (1996) Serum leptin in children with obesity: Relationship to gender and development.
Pediatrics 98:201-203). The logic of having a central hormone of the lipostat involved in gonadal development and puberty is suggested by the relationship between the attainment of required body weight and the onset of puberty (Kennedy, G.C., et al. (1963) Body weight and food intake as initiating factors for puberty in the rat. J. Physiol. 166:408-418; Frisch,
R.E. et al. (1974) Menstrual cycles: Fatness as a determinant of minimum
weight or height necessary for maintenance or onset. Science, 185:949- 951 ; Frisch, R.E. (1980) Pubertal adipose tissue: Is it necessary for normal sexual maturation? Evidence from the rat and human female. Fed. Proc, 39:2395-2400). Body weight or fat are more closely related to puberty than age (Frisch, R.E. et al. (1972) Weight at menarche: Similarity for well nourished and undernourished girls at differing ages and evidence for historical constancy. Pediatrics, 50:445-450), and low body weight or fat are known to delay puberty (Van der Spuy, Z. (1985) Nutrition and reproduction. Clin. Obstet. Gynsecol. 12:579-604). The ob/ob and db/db mice are infertile even though their body weight is abnormally high. Leptin administration to deficient ob/ob mice restores fertility (Chehab, F.F. et al. (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nature Genetics, 12:318- 3207). Leptin administration to starved mice tends to reverse the effects of starvation on testosterone and LH levels (Ahima, R.S. et al. (1996) Leptin is a major mediator of the neuroendocrine response to fasting. Submitted). Additional evidence for a role of leptin in the hypothalamic- pituitary-gonadal axis (HPG) derives from the distribution of the long form of OB-R that is abundant in the gonads as well as the hypothalamus (Lee, G.H. et al. (1996) Abnormal splicing of the leptin receptor in diabetic mice. Nature 379:632-635). The role of neuropeptide Y (NPY) in leptin action also suggests possible involvement in the HPG (Weigie, D.S., et al. (1995) Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J. Clin. Invest. 96:2065-2070). NPY has long been known to alter luteinizing hormone -releasing hormone (LHRH) release and is known to have receptors in the region of the hypothalamus containing LHRH neurons.
These and other data led Ahima et al. to investigate the effects of leptin on the onset of puberty in starved lean mice (Ahima, R.S., et al. (1996) Leptin accelerates the onset of puberty in normal female mice.
Submitted). They found that leptin administered subcutaneously at doses that did not alter weight gain induced an earlier onset of vaginal opening, estrus, and cycling. No relationship was seen, however, between leptin plasma levels and vaginal opening or estradiol.
SUMMARY OF THE INVENTION
Accordingly, a major object of the present invention is to provide a method of treating the infertility associated with improper nutrition. Leptin used as an adjunct in weight loss programs would not only aid the weight loss itself but could prevent fertility problems that were induced by a rapid drop in leptin levels.
The use of leptin receptor ligands represents an opportunity for therapy in conditions associated with either abnormally low or high adiposity, or relative leptin deficiency. For example, infertility in subjects with low adiposity may be restored by exogenous leptin administration. Delayed puberty may be treated with a leptin regimen.
This invention, therefore, discloses the utility of leptin, leptin mimetics, or novel leptin analogs to treat fertility disorders and delayed puberty in either obese or lean subjects. Alternatively, leptin antagonists or neutralizing antileptin antibodies may be used to treat precocious puberty.
With the foregoing and other objects, advantages and features of the invention that will become hereinafter apparent, the nature of the invention may be more clearly understood by reference to the following detailed description of the preferred embodiments of the invention and to the appended claims.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
This invention arose from a desire of the inventors to provide a safe, effective treatment for infertility, in particular a treatment which would prevent or inhibit the infertility associated with improper nutrition in a mammal in need of such treatment.
For purposes of the present invention, as disclosed and claimed herein, the following terms and abbreviations are defined as follows:
Base pair (bp) -- refers to DNA or RNA. The abbreviations A,C,G, and T correspond to the 5'-monophosphate forms of the nucleotides (deoxy)adenine, (deoxy)cytidine, (deoxy)guanine, and (deoxy)thymine, respectively, when they occur in DNA molecules. The abbreviations U,C,G, and T correspond to the 5'-monophosphate forms of the nucleosides uracil, cytidine, guanine, and thymine, respectively when they occur in RNA molecules. In double stranded DNA, base pair may refer to a partnership of A with T or C with G. In a DNA/RNA heteroduplex, base pair may refer to a partnership of T with U or C with G.
Chelating Peptide - An amino acid sequence capable of complexing with a multivalent metal ion. DNA - Deoxyribonucleic acid.
EDTA - an abbreviation for ethylenediamine tetraacetic acid. ED50 — an abbreviation for half-maximal value. FAB-MS -- an abbreviation for fast atom bombardment mass spectrometry. Hypothalamic-Pituitary-Adrenal-Adipose Axis (HPAAA): A physiological regulatory system wherein each of the named elements (the hypothalamus, the pituitary gland, the adrenal glands, and adipose tissue) release chemicals that regulate the activity of the others. For example, CRH released by the hypothalamus stimulates pituitary secretion of ACTH, that in turn stimulates adrenal secretion of glucocorticoids, which in turn
modulates adipose tissue leptin release, that finally acts back on the hypothalamus.
Immunoreactive Protein(s) - a term used to collectively describe antibodies, fragments of antibodies capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived, and single chain polypeptide binding molecules as described in PCT Application No. PCT/US 87/02208, International Publication No. WO 88/01649. mRNA -- messenger RNA. MWCO -- an abbreviation for molecular weight cut-off.
Modulating - stimulation, potentiation, or inhibition of the activity of a receptor or system.
Plasmid -- an extrachromosomal self-replicating genetic element. PMSF -- an abbreviation for phenylmethylsulfonyl fluoride. Reading frame - the nucleotide sequence from which translation occurs "read" in triplets by the translational apparatus of tRNA, ribosomes and associated factors, each triplet corresponding to a particular amino acid. Because each triplet is distinct and of the same length, the coding sequence must be a multiple of three. A base pair insertion or deletion (termed a frameshift mutation) may result in two different proteins being coded for by the same DNA segment. To insure against this, the triplet codons corresponding to the desired polypeptide must be aligned in multiples of three from the initiation codon, i.e. the correct "reading frame" must be maintained. In the creation of fusion proteins containing a chelating peptide, the reading frame of the DNA sequence encoding the structural protein must be maintained in the DNA sequence encoding the chelating peptide.
Receptor agonist - any compound that binds to a receptor and triggers the action of the receptor (usually an intracellular signalling event
or, in the case of receptors that form transmembrane channel, the opening or closing of the channel).
Receptor antagonist - any compound that binds to a receptor and blocks the action of the receptor (usually by out-competing the endogenous agonist for binding sites on the receptor).
Receptor ligand - any compound that binds to a receptor. Recombinant DNA Cloning Vector - any autonomously replicating agent including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been added.
Recombinant DNA Expression Vector - any recombinant DNA cloning vector in which a promoter has been incorporated.
Replicon - A DNA sequence that controls and allows for autonomous replication of a plasmid or other vector. RNA - ribonucleic acid.
RP-HPLC - an abbreviation for reversed-phase high performance liquid chromatography.
Transcription -- the process whereby information contained in a nucleotide sequence of DNA is transferred to a complementary RNA sequence.
Translation - the process whereby the genetic information of messenger RNA is used to specify and direct the synthesis of a polypeptide chain.
Tris - an abbreviation for tris-(hydroxymethyl)aminomethane. Treating - describes the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of a leptin receptor ligand of the present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder. Treating obesity, for example, includes the inhibition of food
intake, the inhibition of weight gain, and inducing weight loss in patients in need thereof.
Vector - a replicon used for the transformation of cells in gene manipulation bearing polynucleotide sequences corresponding to appropriate protein molecules which, when combined with appropriate control sequences, confer specific properties on the host cell to be transformed. Plasmids, viruses, and bacteriophage are suitable vectors, since they are replicons in their own right. Artificial vectors are constructed by cutting and joining DNA molecules from different sources using restriction enzymes and ligases. vectors include Recombinant DNA cloning vectors and Recombinant DNA expression vectors.
X-gal - an abbreviation for 5-bromo-4-chloro-3-idolyl beta-D- galactoside.
Leptin receptor agonists may be used to treat fertility disorders and delayed puberty. Alternatively, leptin antagonists, alone or combined with specific antibodies to leptin, may be used to treat precocious puberty. In addition to the full mature protein, proteins include a leader sequence such as Met-Asp or Met-Arg, or altered primary sequence to achieve higher physical stability.
The inventors have found that administration of leptin receptor ligands, in particular leptin receptor agonists or leptin receptor antagonists, effectively may be used to treat the infertility associated with improper nutrition. The phrases "receptor ligands", "receptor agonists", and "receptor antagonists" used herein are understood to refer to pharmacologically active compounds, and to salts thereof. Preferred leptin receptor agonists for use in the present invention include endogenous leptin (i.e., endogenous OB protein - the protein produced from the obesity gene following transcription and translation and deletion of introns, translation to a protein and processing to the mature protein with secretory
signal peptide removed, e.g., from the N-terminal valine-proline to the C- terminal cysteine of the mature protein). The mouse OB protein and human OB protein are published in Zhang et al., Nature 372:425-432 (1994). The rat OB protein is published in Murakami et al., Biochem. Biophys. Res. Com. 209:944-952 (1995). The porcine and bovine OB genes and proteins are disclosed in EP 0 743 321 , the contents of which are incorporated by reference. Various primate OB genes and proteins are disclosed in U.S. Application Serial No.08/710,483, the contents of which are incorporated by reference. Also preferred for use in the present invention are leptin analogs, preferably leptin analogs having one or more amino acid substitution, more preferably less than five and most preferably less than three substitutions. Particularly preferred leptin analogs for use in the present invention include proteins disclosed by Basinski et al., in WO 96/23515 and WO 96/23517 (the contents of which are incorporated by reference), of the Formula (I):
SEQ ID NO: 1
1 5 10 15
Val Pro He Gin Lys Val Gin Asp Asp Thr Lys Thr Leu He Lys
20 25 30 Thr He Val Thr Arg He Asn Asp He Ser His Thr Xaa Ser Val
35 40 45
Ser Ser Lys Gin Lys Val Thr Gly Leu Asp Phe He Pro Gly Leu
50 55 60
His Pro He Leu Thr Leu Ser Lys Met Asp Gin Thr Leu Ala Val 65 70 75
Tyr Gin Gin He Leu Thr Ser Met Pro Ser Arg Asn Val He Gin
80 85 90
He Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu
95 100 105 Ala Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu
110 115 120
Thr Leu Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser
125 130 135
Thr Glu Val Val Ala Leu Ser Arg Leu Gin Gly Ser Leu Gin Asp
140 145
Met Leu Trp Gin Leu Asp Leu Ser Pro Gly Cys or pharmaceutically acceptable salts thereof, wherein:
Xaa at position 28 is Gin or absent; said protein having at least one of the following substitutions:
Gin at position 4 is replaced with Glu;
Gin at position 7 is replaced with Glu; Asn at position 22 is replaced with Gin or Asp;
Thr at position 27 is replaced with Ala;
Xaa at position 28 is replaced with Glu;
Gin at position 34 is replaced with Glu;
Met at position 54 is replaced with methionine sulfoxide, Leu, lie, Val, Ala, or Gly;
Gin at position 56 is replaced with Glu;
Gin at position 62 is replaced with Glu;
Gin at position 63 is replaced with Glu;
Met at position 68 is replaced with methionine sulfoxide, Leu, lie, Val, Ala, or Gly;
Asn at position 72 is replaced with Gin, Glu, or Asp;
Gin at position 75 is replaced with Glu;
Ser at position 77 is replaced with Ala;
Asn at position 78 is replaced with Gin or Asp; Asn at position 82 is replaced with Gin or Asp;
His at position 97 is replaced with Gin, Asn, Ala, Gly, Ser, or Pro;
Trp at position 100 is replaced with Ala, Glu, Asp, Asn, Met, lie, Phe, Tyr, Ser, Thr, Gly, Gin, Val, or Leu;
Ala at position 101 is replaced with Ser, Asn, Gly, His, Pro, Thr, or Val;
Ser at position 102 is replaced with Arg;
Gly at position 103 is replaced with Ala;
Glu at position 105 is replaced with Gin;
Thr at position 106 is replaced with Lys or Ser;
Leu at position 107 is replaced with Pro; Asp at position 108 is replaced with Glu;
Gly at position 111 is replaced with Asp;
Gly at position 118 is replaced with Leu;
Gin at position 130 is replaced with Glu;
Gin at position 134 is replaced with Glu; Met at position 136 is replaced with methionine sulfoxide, Leu, lie,
Val, Ala, or Gly;
Trp at position 138 is replaced with Ala, Glu, Asp, Asn, Met, lie, Phe, Tyr, Ser, Thr, Gly, Gin, Val, or Leu; or
Gin at position 139 is replaced with Glu. In addition, the leptin receptor ligands of the present invention are optionally substituted with a functional group. Any art-recognized functional group which does not eliminate or significantly reduce the compound's ability to bind to leptin receptors are contemplated, including, but not limited to, ester, amide, acid, amine, alcohol, ether, thioether, etc. Solvates, e.g., hydrates of the compounds useful in the methods of the present invention, are also included within the scope of the present invention. Methods of solvation to produce such solvates are generally known in the art.
Pharmaceutical salts of the leptin receptor agonists and antagonists suitable for administration by a variety of routes are known in the art and need not be described herein in detail. Examples of pharmaceutically acceptable salts of the leptin receptor ligands and derivatives thereof according to the invention, include base salts, e.g., derived from an appropriate base. Pharmaceutically acceptable salts of an acid group or an amino group include, but are not limited to, salts of organic carboxylic
acids such as acetic, lactic, tartaric, malic, isothionic, and lactobionic acids; organic sulfonic acids such as methanesulfonic, ethanesulfonic, benzenesulfonic and p-tolylsuifonic acids, and inorganic acids such as hydrochloric, sulfuric, phosphoric and sulfamic acids. Pharmaceutically- acceptable salts of a compound with a hydroxy group include, but are not limited to, the anion of the compound in combination with a suitable cation such as Na+.
In a further embodiment of the present invention comprises a method for treating the infertility associated with improper nutrition by administration of antibodies to endogenous leptin receptor agonists to a mammal in need of such treatment. Such antibodies may be monoclonal or polyclonal antibodies to leptin receptor agonists, or to antigenic parts thereof.
Both polyclonal and monoclonal antibodies to leptin receptor agonists are obtainable by immunization of an animal with purified leptin receptor agonists, purified recombinant leptin receptor agonists, fragments of these proteins, or purified fusion proteins of leptin receptor agonists, with another protein. In the case of monoclonal antibodies, partially purified proteins or fragments may serve as immunogens. The methods of obtaining both types of antibodies are well known in the art with excellent protocols for antibody production being found in Harlow et al. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 726 pp.
Polyclonal sera are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of purified leptin receptor agonists, or parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Monoclonal antibodies are particularly useful because they can be produced in large quantities and with a high degree of homogeneity. Hybridoma cell lines which produce monoclonal antibodies are prepared
by fusing an immortal cell line with lymphocytes sensitized against the immunogenic preparation and is done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard, I.Y. and Hoffman, T., "Basic Facts About Hybridomas", in Compendium of Immunology, Vol. II, L. Schwartz (Ed.) (1981); Kohler, G. and Milstein, C, Nature 256: 495-497 (1975) and European Journal of Immunology 6: 511- 519 (1976); Harlow et al.; Koprowski, et al., U.S. Patent 4,172,124; Koprowski et al., U.S. Patent 4,196,265 and Wands, U.S. Patent 4,271 ,145, the teachings of which are herein incorporated by reference. A still further part of this invention is a pharmaceutical composition of matter for treating the infertility associated with improper nutrition that comprises at least one of the leptin receptor agonists or antagonists described above, mixtures thereof, and/or pharmaceutical salts thereof, and a pharmaceutically-acceptable carrier therefor. Such compositions are prepared in accordance with accepted pharmaceutical procedures, for example, as described in Remington's Pharmaceutical Sciences, seventeenth edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
For therapeutic use in a method of treating the infertility associated with improper nutrition, a leptin receptor agonist or antagonist, or its salt, can be conveniently administered in the form of a pharmaceutical composition containing one or more leptin receptor agonists or . antagonists, or salts thereof, and a pharmaceutically acceptable carrier therefor. Suitable carriers are well known in the art and vary with the desired form and mode of administration of the pharmaceutical composition. For example, they may include diluents or excipients such as fillers, binders, wetting agents, disintegrators, surface-active agents, lubricants, and the like. Typically, the carrier may be a solid, liquid, or vaporizable carrier, or combinations thereof. In one preferred
embodiment, the composition is a therapeutic composition and the carrier is a pharmaceutically acceptable carrier.
The leptin receptor ligands for use in the present invention, or salts thereof, may be formulated together with the carrier into any desired unit dosage form. Typical unit dosage forms include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, suppositories; injectable solutions and suspensions are particularly preferred.
Each carrier must be "acceptable" in the sense of being compatible with the other ingredients in the formulation and not injurious to the patient. The carrier must be biologically acceptable and inert, i.e., it must permit the cell to conduct its metabolic reactions so that the leptin receptor ligands suitable for use in the method of the present invention may effect its inhibitory activity.
Formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and transdermal) administration, with topical ointment formulations, and formulations appropriate for oral administration, being preferred.
For example, to prepare formulations suitable for injection, solutions and suspensions are sterilized and are preferably isotonic to blood. In making injectable preparations, carriers which are commonly used in this field can also be used, for example, water, ethyl alcohol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitate esters. In these instances, adequate amounts of isotonicity adjusters such as sodium chloride, glucose or glycerin can be added to make the preparations isotonic. The aqueous sterile injection solutions may further contain anti-oxidants, buffers, bacteriostats, and like additions acceptable for parenteral formulations.
The formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which may encompass one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product. Various unit dose and multidose containers, e.g., sealed ampules and vials, may be used, as is well known in the art. In addition to the ingredients particularly mentioned above, the formulations of this invention may also include other agents conventional in the art for this type of pharmaceutical formulation.
The leptin receptor ligands suitable for use in the present invention may be present in the composition in an broad proportion to the carrier. For instance, the leptin receptor ligands may be present in the amount of 0.01 to 99.9 wt%, and more preferably in about 0.1 to 99 wt%. Still more preferably, the leptin receptor ligand may be present in an amount of about 1 to 70 wt% of the composition.
The dosage of the leptin receptor agonists or antagonists, pharmaceutically acceptable salts thereof, or mixtures thereof administered to a patient according to the present invention will vary depending on several factors, including, but not limited to, the age, weight, and species of the patient, the general health of the patient, the severity of the symptoms, whether the composition is being administered alone or in combination with other therapeutic agents, the incidence of side effects and the like.
In general, a dose suitable for application in treating the infertility associated with improper nutrition is about 0.001 to 100 mg/kg body weight/dose, preferably about 0.01 to 60 mg/kg body weight/dose, and still more preferably about 0.1 to 40 mg/kg body weight/dose per day. The
desired dose may be administered as 1 to 6 or more subdoses administered at appropriate intervals throughout the day. The leptin receptor ligands may be administered repeatedly over a period of months or years, or it may be slowly and constantly infused to the patient. Higher and lower doses may also be administered.
The daily dose may be adjusted taking into account, for example, the above-identified variety of parameters. Typically, the present compositions may be administered in an amount of about 0.001 to 100 mg/kg body weight/day. However, other amounts may also be administered.
To achieve good plasma concentrations, leptin receptor ligands suitable for use in the present invention may be administered, for instance, by intravenous injection of an approximate 0.1 to 1% solution of the active ingredient, optionally in saline, or orally administered as a bolus. The active ingredient may be administered for therapy by any suitable routes, including topical, oral, rectal, nasal, vaginal and parenteral (including intraperitoneal, subcutaneous, intramuscular, intravenous, intradermal, and transdermal) routes. It will be appreciated that the preferred route will vary with the condition and age of the patient, the nature of the disorder and the chosen active ingredient including other therapeutic agents. Preferred is the oral route. Also preferred is the topical route. However, other routes may also be utilized depending on the conditions of the patient and how long-lasting the treatment is.
While it is possible for the active ingredient to be administered alone, it is preferably present as a pharmaceutical formulation. The formulations of the present invention comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents.
The above method may be practiced by administration of leptin receptor ligands by themselves or in a combination with other active
ingredients, including therapeutic agents in a pharmaceutical composition. Other therapeutic agents suitable for use herein are any compatible drugs that are effective by the same or other mechanisms for the intended purpose, or drugs that are complementary to those of the present agents. These include agents that are effective for the treatment of infertility and/or associated conditions in humans.
The compounds utilized in combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times than the present compounds, e.g., sequentially, such that a combined effect is achieved. The amounts and regime of administration will be adjusted by the practitioner, by preferably initially lowering their standard doses and then titrating the results obtained. The therapeutic method of the invention may be used in conjunction with other therapies as determined by the practitioner. While the invention has been described and illustrated herein by references to various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material, combinations of material, and procedures selected for that purpose. Numerous variations of such details can be implied and will be appreciated by those skilled in the art.
Claims
1. A method of treating the infertility associated with improper nutrition comprising administering to a mammal in need of such treatment a leptin receptor ligand in an amount effective to induce fertility.
2. The method of claim 1, wherein said leptin receptor ligand is a leptin receptor agonist.
3. The method of claim 2, wherein said leptin receptor agonist is human leptin.
4. The method of claim 2, wherein said leptin receptor agonist has the amino acid sequence of SEQ ID NO: 1.
5. The method of claim 1, wherein said leptin receptor ligand is a leptin receptor antagonist.
6. The method of claim 1, wherein the leptin receptor ligand is administered in an amount of about 0.001 to 100 mg/kg body weight/dose.
7. The method of claim 1, wherein the leptin receptor ligand is administered orally, intravenously, subcutaneously, topically, transdermally, intramuscularly, or intraperitoneally.
8. The method of claim 1, wherein the leptin receptor ligand is administered orally.
9. The method of claim 1, wherein the composition is administered intravenously.
10. The method of claim 1, wherein the leptin receptor ligand is administered in the form of a pharmaceutical composition of matter which further comprises a pharmaceutically-acceptable carrier.
11. A method of treating precocious puberty comprising administering to a mammal in need of such treatment an amount of a specific antibody to a leptin receptor agomst effective to reverse precocious puberty.
12. A method of treating precocious puberty comprising administering to a mammal in need of such treatment an amount of a leptin receptor antagonist effective to reverse precocious puberty.
13. A method of treating delayed puberty comprising administering to a mammal in need of such treatment an amount of a leptin receptor agonist effective to induce puberty.
14. A pharmaceutical composition of matter for treating the infertility associated with improper nutrition, comprising a leptin receptor ligand in an amount effective to induce fertility, and a pharmaceutically acceptable carrier therefor.
15. The composition of claim 14, wherein said leptin receptor ligand is a leptin receptor agonist.
16. The composition of claim 14, wherein said leptin receptor ligand is a leptin receptor antagonist.
17. A pharmaceutical composition of matter for treating precocious puberty, comprising specific antibodies to a leptin receptor agonist effective to reverse precocious puberty, and a pharmaceutically acceptable carrier therefor.
18. A pharmaceutical composition of matter for treating precocious puberty, comprising a leptin receptor antagonist in an amount effective to reverse precocious puberty, and a pharmaceutically acceptable carrier therefor.
19. A pharmaceutical composition of matter for treating delayed puberty, comprising a leptin receptor agonist in an amount effective to induce puberty, and a pharmaceutically acceptable carrier therefor.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP53675198A JP2001512483A (en) | 1997-02-25 | 1998-02-24 | Treatment of infertility with leptin receptor ligand |
EP98908555A EP0991419A1 (en) | 1997-02-25 | 1998-02-24 | Treatment of infertility with leptin receptor ligands |
AU66560/98A AU6656098A (en) | 1997-02-25 | 1998-02-24 | Treatment of infertility with leptin receptor ligands |
CA002281888A CA2281888A1 (en) | 1997-02-25 | 1998-02-24 | Treatment of infertility with leptin receptor ligands |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80610497A | 1997-02-25 | 1997-02-25 | |
US08/806,104 | 1997-02-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998036763A1 WO1998036763A1 (en) | 1998-08-27 |
WO1998036763A9 true WO1998036763A9 (en) | 1999-02-11 |
Family
ID=25193331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/002909 WO1998036763A1 (en) | 1997-02-25 | 1998-02-24 | Treatment of infertility with leptin receptor ligands |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0991419A1 (en) |
JP (1) | JP2001512483A (en) |
AU (1) | AU6656098A (en) |
CA (1) | CA2281888A1 (en) |
WO (1) | WO1998036763A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045559A1 (en) | 1996-05-29 | 1997-12-04 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
US6777388B1 (en) | 1998-08-21 | 2004-08-17 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
US7208572B2 (en) | 1998-08-21 | 2007-04-24 | Albany Medical College | Leptin-related peptides |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
IL146655A0 (en) * | 2001-11-21 | 2002-07-25 | Yeda Res & Dev | The use of leptin in fertility |
CN1961000B (en) | 2004-02-11 | 2011-05-04 | 安米林药品公司 | Hybrid polypeptides with selectable properties |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
US8404637B2 (en) | 2005-02-11 | 2013-03-26 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
BRPI0614649A2 (en) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | hybrid polypeptides with selectable properties |
WO2007025349A1 (en) * | 2005-09-01 | 2007-03-08 | The University Of New England | Modulating ovulation and growth rates |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
CN104360086B (en) * | 2014-12-05 | 2016-06-15 | 重庆中元生物技术有限公司 | The latex enhancing immune of a kind of soluble leptin receptor is than turbid detection kit |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996023815A1 (en) * | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Ob gene product antibodies |
GB9509164D0 (en) * | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
WO1996035787A1 (en) * | 1995-05-08 | 1996-11-14 | Chiron Corporation | Nucleic acids for treating obesity |
WO1996040912A1 (en) * | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
-
1998
- 1998-02-24 JP JP53675198A patent/JP2001512483A/en active Pending
- 1998-02-24 CA CA002281888A patent/CA2281888A1/en not_active Abandoned
- 1998-02-24 AU AU66560/98A patent/AU6656098A/en not_active Abandoned
- 1998-02-24 EP EP98908555A patent/EP0991419A1/en not_active Withdrawn
- 1998-02-24 WO PCT/US1998/002909 patent/WO1998036763A1/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998036763A9 (en) | Treatment of infertility with leptin receptor ligands | |
WO1998036763A1 (en) | Treatment of infertility with leptin receptor ligands | |
JP3366644B2 (en) | Treatment of partial growth hormone insensitivity syndrome | |
AU623447B2 (en) | Binding protein for insulin-like growth factors | |
EP2631244A1 (en) | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them | |
TW200529868A (en) | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof | |
US20230139407A1 (en) | Recombinant fsh composition for treatment of infertility | |
US20100196330A1 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
WO2004096853A1 (en) | Combined use of keratinocyte growth factor agonists and gastrin compounds | |
WO1998036762A1 (en) | Method of modulating hypothalamic somatostatin release | |
KR20040039320A (en) | A Method of Constructing Nonchimeric Analogs of Human Hormones | |
WO1998036769A1 (en) | Pulsatile delivery of leptin receptor ligands | |
EP1117425A2 (en) | Methods for the treatment of non-thyroid disorders | |
EP0784981A2 (en) | Obesity protein formulations | |
EP0784982A2 (en) | Obesity protein formulations | |
WO1998036767A1 (en) | Modulation of the hypothalamic-pituitary-adrenal-adipose axis with leptin receptor ligands | |
EP0835879A2 (en) | Analogs of obesity proteins and pharmaceutical formulations comprising them | |
EP1128840A1 (en) | Prevention of muscle mass loss with leptin receptor ligands | |
WO1998007446A1 (en) | Protein formulations | |
KR20220157911A (en) | Composition For Preventing or Treating Non-Alcoholic Fatty Liver Disease or Non-Alcoholic Steatohepatitis Comprising Growth Differentiation Factor-15 Variant | |
KR100497685B1 (en) | Glycoprotein Hormone Superactive Drug | |
AU703556B2 (en) | Human galanin, cDNA clones encoding human galanin and a method of producing human galanin | |
EP0889737A1 (en) | Obesity protein compounds and formulations thereof | |
JPH1080277A (en) | Variant human growth hormone and its use | |
WO1998031391A1 (en) | Obesity protein formulations |